The receptor tyrosine kinases: role in cancer progression - PubMed (original) (raw)

Review

. 2001 Apr;10(2):271-88, viii.

Affiliations

• PMID: 11382587

Review

The receptor tyrosine kinases: role in cancer progression

L Lamorte et al. Surg Oncol Clin N Am. 2001 Apr.

Abstract

The last two decades have witnessed significant progress in the understanding of the basic mechanisms underlying tumor growth and metastasis. Receptor tyrosine kinases play a central role in cell proliferation and differentiation, cell survival, cell motility, invasion, and angiogenesis, all of which contribute to tumor progression. Alterations at the level of the receptor and its ligand lead to the activation of a number of signaling pathways, each of which may contribute to cancer progression. The dissection of the molecular changes associated with neoplastic growth have provided pharmaceutical companies with a range of targets for drug intervention. This article highlights the deregulation of receptor tyrosine kinases in human cancers and their involvement in metastasis.

PubMed Disclaimer

Similar articles

• Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
  Chung LW, Baseman A, Assikis V, Zhau HE. Chung LW, et al. J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10. J Urol. 2005. PMID: 15592017 Review.
• Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
  Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Sigalotti L, et al. J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.
• Rational bases for the development of EGFR inhibitors for cancer treatment.
  Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Bianco R, et al. Int J Biochem Cell Biol. 2007;39(7-8):1416-31. doi: 10.1016/j.biocel.2007.05.008. Epub 2007 May 21. Int J Biochem Cell Biol. 2007. PMID: 17596994 Review.
• Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
  Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C. Sabbah M, et al. Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Drug Resist Updat. 2008. PMID: 18718806 Review.
• The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis.
  Samani AA, Brodt P. Samani AA, et al. Surg Oncol Clin N Am. 2001 Apr;10(2):289-312, viii. Surg Oncol Clin N Am. 2001. PMID: 11382588 Review.

Cited by

• Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions.
  Al-Ghabkari A, Huang B, Park M. Al-Ghabkari A, et al. Cells. 2024 Jan 25;13(3):218. doi: 10.3390/cells13030218. Cells. 2024. PMID: 38334610 Free PMC article. Review.
• Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.
  Lamorte L, Royal I, Naujokas M, Park M. Lamorte L, et al. Mol Biol Cell. 2002 May;13(5):1449-61. doi: 10.1091/mbc.01-10-0477. Mol Biol Cell. 2002. PMID: 12006644 Free PMC article.
• A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.
  Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, Leachman S, Cannon-Albright LA. Teerlink CC, et al. J Natl Cancer Inst. 2018 Dec 1;110(12):1380-1385. doi: 10.1093/jnci/djy058. J Natl Cancer Inst. 2018. PMID: 29659923 Free PMC article.
• Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.
  Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Stephenson SA, et al. BMC Mol Biol. 2001;2:15. doi: 10.1186/1471-2199-2-15. Epub 2001 Dec 21. BMC Mol Biol. 2001. PMID: 11801186 Free PMC article.
• Receptor tyrosine kinase inhibitors in cancer.
  Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, Ghanaatian M, Rezaei-Tazangi F, Baziyar P, Ahmadi A, Hamblin MR, Aref AR. Ebrahimi N, et al. Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4. Cell Mol Life Sci. 2023. PMID: 36947256 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database